Disclaimer: This is not financial advice, and investors should conduct their own due diligence before making any investment decisions.
Tiger's Take
With $110 million in funding to date, Carlsmed generated $32M in annual revenue while incurring a $25M net loss, signaling a need for improved financial discipline and a clear path to profitability. I would wait this stock out to see if they can execute the business to profitability in 2026.
S-1 Summary
Carlsmed has filed its S-1 with the SEC, and below is a summary of the S-1 so you don't have to read the whole thing. I did it for you.
Technolo...
